Background-Radiofrequency ablation of multiple or unmappable ventricular tachycardias (VTs) remains a challenge with unclear end points. We present our experience with a new strategy isolating core elements of VT circuits. Methods and Results-Patients with structural heart disease presenting for VT radiofrequency ablation at 2 centers were included. Strategy involved entrainment/activation mapping if VT was hemodynamically stable, and voltage mapping with electrogram analysis and pacemapping. Core isolation (CI) was performed incorporating putative isthmus and early exit site(s) based on standard criteria. If VT was noninducible, the dense scar (<0.5 mV) region was isolated. Successful CI was defined by exit block (20 mA at 2 ms) within the isolated region. VT inducibility was also assessed. Forty-four patients were included (mean age, 63; 95% male; 73% ischemic cardiomyopathy; mean left ventricular ejection fraction, 31%; 68% with multiple unstable VTs [mean, 3+2]). CI area was 11+12 versus 55+40 cm 2 total scar area. Additional substrate modification was performed in 27 (61%), and epicardial radiofrequency ablation was performed in 4 (9%) patients. CI was achieved in 37 (84%) and led to better VT-free survival (log rank P=0.013). Conclusions-CI is a novel strategy with a discrete and measurable end point beyond VT inducibility to treat patients with multiple or unmappable VTs. The CI region can be selected based on standard characterization of suspected VT isthmus surrogates thus limiting ablation target size. Exit block within the isolated area is achievable in most and may further improve long-term success. (Circ Arrhythm Electrophysiol. 2015;8:353-361.
C
atheter ablation has become a mainstay for management of drug-refractory ventricular tachycardia (VT) among patients with structural heart disease. [1] [2] [3] [4] Substrate-based ablation in particular has emerged as an integral component of the procedure, especially among the majority of patients in whom there are multiple VTs, or VTs are not able to be mapped via standard entrainment methods. 1, 2, 5, 6 This technique has subsequently helped to increase the treatable population and provide incremental gains in prevention of recurrent VTs and implantable cardioverter defibrillator (ICD) therapies. [5] [6] [7] [8] However, long-term success rates remain suboptimal and have likely been limited by lack of a clearly defined or reproducible ablation end point. Acute noninducibility of VT after ablation has been the standard end point, 4 but it has inherent limitations. First, lack of inducibility before ablation confounds interpretation of noninducibility after ablation. Second, there is a known lack of reproducibility in inducing VT, especially in the setting of concomitant antiarrhythmic drug (AAD) use. Third, changes in autonomic tone and use of general anesthesia may affect VT inducibility. Fourth, ablation lesions may either expand as a result of disruption of microcirculation, with consequent myocyte loss, or regress secondary to healing and resolution of edema. Finally, patients may be too unstable to tolerate additional attempts at VT induction after ablation. 4, [7] [8] [9] [10] [11] Several alternative end points have been studied recently, including diffusely targeting regions with abnormal electrograms, and empirical isolation of the entire region of abnormal electrograms. 8, [12] [13] [14] We sought to investigate a unique ablation end point among patients with VT in the setting of structural heart disease by (1) identifying critical or core VT circuit elements based on careful electrophysiological characterization and (2) ablating these areas circumferentially with the goal of achieving electric isolation. Core isolation (CI) thus refers to circumferential ablation around all critical VT circuit elements. We present combined experiences from 2 tertiary referral centers using this novel technique of CI.
institutional guidelines of each health system, all patients provided written informed consent both for VT ablation, and for their anonymized medical information to be included in research studies. All included patients had structural heart disease and VT that was refractory to AAD therapy. All underwent detailed electroanatomic mapping and ablation of the endocardium or epicardium using an open-irrigated 3.5-mm-electrode-tip catheter (ThermoCool or ThermoCool SF, Biosense Webster, Diamond Bar, CA) and electroanatomic mapping system (CARTO, Biosense Webster). Included patients underwent ablation with intent to achieve CI (see below). Exclusion criteria included <18 years of age, lack of low-voltage regions as determined by bipolar voltage mapping (see below), inability or refusal to provide informed consent, or individual operator decision before starting the case not to attempt CI as the ablation strategy.
Electrophysiology Study and Mapping
Endocardial access was obtained to the left ventricle using retrograde transaortic or transseptal approach and to the right ventricle (RV) using transvenous approach. When necessary, transcutaneous, subxiphoid epicardial access was obtained using fluoroscopic guidance as previously described. 15 Heparin was administered throughout all procedures involving left-sided intracardiac access to maintain activated clotting times of 200 to 350 seconds. Heparin was occasionally administered during intracardiac RV access at operator discretion.
Mapping in sinus or paced rhythm was performed at the outset as follows. Voltage mapping was performed to identify areas of scar, with bipolar electrogram amplitudes of <0.5 mV defining areas of dense scar; 0.5 to 1.5 mV corresponding with endocardial scar border zone (0.5-1.0 mV for epicardial scar border zone 16 ); and >1.5 mV to delineate normal endocardial tissue 2 (>1.0 mV on epicardium). Potential channels within dense scar were additionally identified by adjusting the color scale display. 17, 18 Sites with fractionated electrograms or late potentials within or adjacent to areas of dense scar were also identified. Pacemapping was performed at sites within channels as noted above, in defined areas containing abnormal electrograms, and in regions in which VT exits were suspected based on 12-lead ECGs, when available. Potential isthmus or exit sites were identified by pacemapping, as previously defined: long stimulus-QRS times (>40 ms) and ≥1 of the following: (1) ≥10 of 12 morphology match to clinical or induced VTs; (2) overall paced QRS vector concordance with clinical or induced VTs (based on bundle branch morphology in V1, frontal plane axis within 30°, and precordial transition occurring at the same lead); or (3) sites in which alternating QRS morphologies were observed with pacing. 2, 19, 20 These areas were annotated on the substrate maps.
Ventricular programmed electric stimulation was performed using ≤2 pacing drive cycle lengths (600 and 400 ms) and ≤3 extrastimuli from ≥1 RV or left ventricle sites. The standard programmed electric stimulation site was the RV apex, if VT was easily inducible with up to triple extrastimuli. If VT was inconsistently inducible, noninducible, 
WHAT IS KNOWN
• Substrate-based catheter ablation techniques are increasingly used to treat refractory scarrelated ventricular tachycardias; however, end points can be difficult to assess and long-term outcomes have remained suboptimal.
WHAT THE STUDY ADDS
• We propose a novel substrate-based ablation approach with the goal of electrically isolating the segment of low voltage scar that is the core of the ventricular tachycardia substrate with evidence of exit block.
• In this feasibility study this technique was achievable in most patients and had outcomes similar to other substrate-based approaches, but with possibly more limited ablation.
or only inducible with triple extrasimuli at the RV apex, other sites (left ventricle or RV) were used at operator discretion. Therefore, all patients underwent at least single-site RV programmed stimulation with up to triple extrastimuli. Additional ventricular pacing maneuvers (burst pacing, with or without isoproterenol or epinephrine) were performed at the operator's discretion with the intention of VT induction. If VT was hemodynamically tolerated, activation and entrainment mapping using standard maneuvers were performed to identify potential isthmus sites. 21 Ablation was delivered when such sites were identified; those with termination without ectopy were considered to be essential VT circuitry sites. VT induction was attempted pre and post ablation unless there safety limitations or other factors considered prohibitive based on operator discretion.
Ablation Strategy and CI
The first step in the ablation procedure was to attempt CI within the dense scar (<0.5 mV) by circumferentially surrounding the putative isthmus or entrance and early exit site(s), which were identified based on pacemapping or entrainment mapping. Sites with ablation termination were uniformly incorporated within CI regions (Figures 1 and  2 ). Regions with electrogram voltage <1.0 mV were also targeted if there were features consistent with isthmus, entrance, or early exit sites, as defined above. If VT was noninducible at the outset and 12-lead VT ECGs were unavailable, circumferential ablation around dense scar (<0.5 mV) was performed. Therefore, the CI area incorporated critical VT circuit elements confirmed by electrophysiological data or dense but electrically excitable scar as specified (Figure 1 ). Individual-point radiofrequency energy delivery using an irrigatedtip ablation catheter, as above, was routinely titrated to achieve 10-to 15-ohm impedance drops, maximum temperature of 45°, and duration of 90 seconds. Longer lesions were delivered when insufficient changes were noted in electrogram or impedance, or lesion depth, as observed on intracardiac echocardiography.
Successful CI was defined by failure to capture the ventricle with pacing from inside the lesion set (exit block) using a pacing output of 20 mA and pulse width of 2 ms from multiple (≥3), discrete sites that had previously demonstrated capture. In all patients, capture from multiple sites was documented before to isolation. Importantly, pacing before and after was not performed at sites of radiofrequency lesion placement. Such an approach has been previously shown to be effective for assessing exit block and effective PV isolation. 22 We noted dissociation of late potentials from ventricular activation (entrance block; Figure 3 ) and isolated firing as additional evidence, although the latter were not required for defining CI. CI was assessed at multiple sites within the isolated region to confirm isolation within the lesion set and not just a segmental effect. CI efficacy was typically assessed after a circumferential lesion set was completed around the region of interest. Pacing was usually performed with a standard ablation catheter. In selected instances, simultaneous multi-electrode catheters were used.
Next, additional, reinforcing lesions were placed at each operator's discretion within the isolated area targeting sites of fractionated electrograms and late potentials noted in sinus rhythm. Although these persistent signals may have represented far-field (midmyocardial or epicardial) activation, additional ablation reinforcing previous lines was occasionally performed to minimize the possibility of lack of 
from patients with ischemic (A and B) and nonischemic cardiomyopathy (C). Ablation lesions are shown (red dots).
A, A relatively unique case in which isthmus, exit, and entrance sites were identified for a hemodynamically tolerated, clinical ventricular tachycardia (VT). Only a region surrounding a critical isthmus region was isolated. B, Exits (arrows and associated VT morphologies) for multiple, unstable VTs were determined, based on pacemapping and limited entrainment and activation mapping, throughout border-zone regions around a large, anteroapical infarction. The targeted core based on these findings incorporated most of the dense scar (electrogram voltage ≤0.5 mV). C, VT could not be induced at the start of the procedure, so ablation incorporated only regions of dense scar (bipolar voltage ≤0.5 mV), with limited inclusion of adjacent late potential sites with favorable pacemap characteristics as described in the text. CI was achieved in each example, and VT was noninducible and has not recurred in follow-up. Examples in B and C were more representative of the majority of cases in this series.
entrance block as an explanation for the persistent signals. Ventricular programmed electric stimulation was repeated after CI, using the same or more aggressive stimulation protocol as that used for initial induction, within limits described above, and whenever patient stability allowed. If any VT was still inducible after CI, other abnormal regions within scar but potentially outside of the isolated region were targeted as needed, based on the morphology of VT(s) induced after reconfirming CI and guided by sites with late potentials and favorable pacemap characteristics, as above. 20 Efforts to achieve CI and VT nonducibility continued as long as patient safety and tolerance allowed with emphasis on assuring continuity of lesions with targeted 12-to 15-ohm impedance drop and ≥90-second duration.
Finally, epicardial mapping and ablation were performed in limited cases because of (1) continued inducibility of VT after endocardial ablation; (2) prior failed endocardial ablation; (3) 12-lead ECG VT characteristics suggesting epicardial exit 23 ; or (4) lack of abnormal endocardial substrate. When epicardial ablation was considered, coronary angiography was performed to ensure a safe distance from major coronary arteries. Ablation was not performed within 1 cm of a major coronary artery or sites of persistent phrenic nerve capture with high-output pacing. Details of defining the CI region for ablation was similar to that performed on the endocardium except that bipolar voltage cut-offs differed as noted. 
Follow-up
Immediately postprocedure, patients were observed in the hospital until clinically stable for discharge. Noninvasive programmed stimulation (NIPS) was performed within 7 days of ablation or before discharge unless contraindicated and as previously described. 9 If VT recurred during follow-up, additional treatments were performed as needed, including AADs, repeat ablation, or surgery. Any VT lasting >30 seconds or leading to syncope or appropriate ICD therapy was considered a VT recurrence. After ablation, AADs were continued at operator discretion. Typically, amiodarone was reduced to ≤200 mg/d. Routinely, AAD would be continued for ≈3 months post procedure and then discontinued if there were no change in clinical status. After discharge, patients were followed at 1 to 3 months and then every 3 to 6 months, or more frequently in the case of arrhythmia recurrence or other clinical events. Visits included both clinical and ICD evaluation. Outcomes evaluated included VT recurrence, complications, and change in AAD regimen. Data, including device interrogation information, were collected from the electronic medical records at the performing institution or by consultation with the patient's cardiologist.
Statistical Analysis
Contiguous areas of abnormal bipolar voltage were measured using the surface area measurement tool on CARTO3 software. Continuous data are reported as mean±SD or median, 25% to 75% interquartile range for non-normally distributed variables, and categorical data are reported as number (%). Two-sided Student t test was used for comparison of continuous variables; the Mann-Whitney test was used for nonparametric comparative testing. Fisher exact test was used for comparison of proportions. Cox proportional Hazard analysis was used to evaluate significant univariate predictors for time to ventricular arrhythmia recurrence, and results are reported as hazard ratio (95% confidence interval). Multivariate analysis was not performed because of low number of events. Kaplan-Meier survival analysis was performed evaluating VT-free survival after ablation comparing those in whom CI was achieved to those in whom CI was not achieved. Log-rank test was used for comparison of survival curves. A P value of <0.05 was considered statistically significant. IBM SPSS Statistics (Version 21, New York) was used for statistical analysis. 
Results

Patient Characteristics
A total of 566 patients with structural heart disease underwent VT ablation between January 2011 and November 2013 at the University of Pennsylvania and University of Colorado. Of these, 44 underwent attempted CI (28 at the University of Pennsylvania, and 16 at the University of Colorado) and were included in this study. The main reason for exclusion was individual operator preference to not try the approach before each case, regardless of patient characteristics. All had core elements identified, and the CI technique was applied to each patient once. Baseline characteristics of the cohort are listed in Table 1 . The mean age was 63±14 years, the majority of patients were male, and more than half had undergone prior VT ablation. The most common preablation AAD was amiodarone (daily oral dose 150±170 mg). Most had a prior history of myocardial infarction and associated ischemic cardiomyopathy. There were 3 patients with arrhythmogenic right ventricular cardiomyopathy, 2 patients with surgically repaired tetralogy of Fallot, 1 patient with cardiac sarcoidosis, 1 patient with hypertrophic cardiomyopathy, and 1 patient with mixed cardiomyopathy (cardiomyopathy out of proportion to coronary artery disease distribution) included in the series. Nearly half of them presented with VT/ventricular fibrillation storm or incessant VT, and most presented with multiple unstable VTs. Extracorporeal membrane oxygenation circuit was placed in 1 patient, and intra-aortic balloon pump was present in 2 patients because of hemodynamic instability before VT ablation. Otherwise, no mechanical hemodynamic support was required or added for these ablation procedures (Table 1) .
Procedural Data and Acute Success
All patients underwent detailed endocardial electroanatomic mapping (522±317 points). Six patients additionally underwent epicardial mapping (456±499 points), 4 of whom had idiopathic cardiomyopathy and 2 of whom had ischemic cardiomyopathy; only 5 underwent epicardial ablation because of proximity of ablation targets to major coronary arteries in 1 of the patients with idiopathic cardiomyopathy. The latter patient was also the only patient with nonischemic VT substrate for whom CI was unable to be achieved because of para-Hisian location of targeted core and desire not to cause complete heart block. VT was unable to be mapped (hemodynamically unstable in 20 [45%] or noninducible in 10 [23%]) in the majority of patients. Isoproterenol was used in 9 (20%) and epinephrine was used in 1 (2%) of the patients, for VT induction. CI was confirmed in 37 patients (84%; Table 2 ). The mean CI area was smaller than the total scar (bipolar electrogram amplitude ≤1.5 mV) area (11±12 versus 55±40 cm 2 ). Patients in whom CI was not achieved tended to have lower left ventricular ejection fraction (23 versus 32%), although this difference was not statistically significant (P=0.07; Table 3 ). There were no significant baseline differences between patients in whom CI could and could not be achieved, including number of prior ablations, mapping points obtained, and disease substrate (Table 3) . Among patients in whom CI was not achieved (n=7), all but 1, noted above, had ischemic substrate, 5 of whom had anterior, and 1 of whom had inferior scar. Two of the patients in whom CI could not be achieved additionally underwent epicardial mapping, but only 1 underwent additional epicardial ablation. Notably, CI could be achieved in 11 of the 12 patients (92%) with a nonischemic VT substrate.
After CI alone, VT was still acutely inducible in 12 (27%) patients. Of these, 3 had clinical VT still inducible, as determined by morphology. The cycle lengths of these VTs were slower or unchanged from before. Additional, substrate ablation was then performed, depending on morphology of persistently inducible VTs after CI. After CI and additional substrate modification outside the area of CI if needed, VT remained inducible in 7 patients, 2 (5%) of whom had clinical VT still inducible and 5 (11%) of whom had only nonclinical VT inducible. There was no statistically significant association between CI and performing additional substrate modification or acute VT noninducibility (Table 3) . Among the few patients who underwent additional epicardial ablation, the CI region targeted for ablation was similar in location to that on the endocardium.
NIPS was performed in 25 (57%) of the patients 3±2 days after the index procedure. Reasons for not performing NIPS were discharge over weekend and subsequent follow-up with another provider remote in location from our institutions or medical contraindication. Of those who underwent NIPS, 14 (56%) were noninducible for any VT. Of the 11 that were Values are reported in mean±SD, median, 25% to 75% interquartile range, or n (%). LVEF indicates left ventricular ejection fraction; and VT, ventricular tachycardia.
inducible on NIPS, 10 (91%) were inducible only for VT that had not been previously observed or induced. The single patient with inducible clinical VT at NIPS did not undergo repeat ablation before discharge but did have amiodarone reinitiated. The others for whom VT was inducible at NIPS were either maintained on the same or reduced antiarrhythmic regimen (usually amiodarone). No additional ablations were performed based on the results of NIPS. There was no significant association between CI and inducibility at NIPS (Table 3) .
Intermediate-Term Success and Predictors of Recurrence
During a follow-up of 17.5±9.0 months (range, 4.2-35.6 months), 38 patients (86%) were free of recurrent sustained ventricular arrhythmias after CI. Of the remaining 6, 3 received single appropriate ICD shocks or ATP for which AAD doses were resumed/increased and they have not had any further recurrences. Two underwent cardiac surgery after VT recurrence: heart transplant in 1, and pseudoaneurysm resection with mitral valve replacement in the other. The remaining patient with recurrent VT underwent repeat ablation at another facility 6.7 months after the index procedure. Data from that ablation are not available. Achievement of CI provided incremental improvement in long-term freedom from VT, even in the absence of achieving acute VT noninducibility (Figure 4) .
None of the patients with VT recurrence was presented in VT storm. Additionally, amiodarone doses tended to be decreased (from 0, 0-300 mg to 0, 0-200 mg; P=0.18) after ablation, although the difference by nonparametric testing did not meet statistical significance.
The only characteristic that was significantly associated with long-term VT recurrence in univariate analysis was achievement of CI (hazard ratio, 0.17; P=0.03; Table 4 ). Notably, neither additional substrate modification beyond CI (P=0.75) nor acute VT noninducibility (P=0.12) was significantly associated with long-term recurrence (Table 4) . Kaplan-Meier survival analysis demonstrated that those in whom CI was successfully achieved had significantly better long-term VT-free survival compared with those in whom CI was not successful (log-rank P=0.013; Figure 5 ).
Complications
The only complications were periprocedural and included pseudoaneurysm at the site of intra-aortic balloon pump placement (n=1) that resolved without intervention and transient hypotension (n=1) that resolved without subsequent incident. There were no cases of pericardial effusion or tamponade, thromboembolic events, hemorrhage, major vascular complications, or deaths.
Discussion
Results from this observational study demonstrate that CI is feasible and seems to be an effective catheter ablation strategy with a discrete and measurable end point beyond VT noninducibility to treat patients with structural heart disease and multiple or unmappable VTs. Importantly, the relative ablation target size may be limited by selecting the CI region based on standard characterization of suspected VT circuit surrogates. CI is achievable in most, and achieving it may further improve long-term success. In our series combining recent experiences from 2 tertiary referral centers, 86% of patients remain free from recurrent ventricular arrhythmias or ICD shocks after CI procedure. Importantly, this VT control Values are reported in mean±SD, median, 25% to 75% interquartile range, or n (%). CI indicates core isolation; NIPS, noninvasive programmed stimulation; and VT, ventricular tachycardia.
*Twenty-five patients underwent NIPS procedure within 7 days after ablation, and 21 of whom had CI achieved. Clinical VT inducible after ablation 3
Any inducible VT after ablation 7 (18) Values are reported in mean±SD, median, 25% to 75% interquartile range, or n (%). VT indicates ventricular tachycardia.
*All patients who underwent epicardial ablation also had endocardial ablation.
has been accomplished with an overall reduction in amiodarone use and with no major complications. Given the inconsistencies between achieving acute VT noninducibility and predicting arrhythmia-free survival longterm, [6] [7] [8] [9] [10] [11] 24 several alternative end points for VT ablation have been proposed. These end points have included identification and elimination of conducting channels, 17, 25 sites indicative of diseased conduction, for example, late potentials or local abnormal ventricular activities, 12, 13, [26] [27] [28] sites with good pace maps or pace-map characteristics, 28 as well as diffuse scar isolation or homogenization. 8, 14 In almost all cases, these strategies were used in conjunction with VT noninducibility as collective end points, many involved a substantial amount of empirical ablation, and several of the techniques were only applied to patients with ischemic heart disease. 8, 14, 25, 28 In this study, additional substrate modification was performed in many of the patients because of continued VT inducibility or operator preference to place reinforcing lesions in those in whom CI had already been achieved. However, doing so did not affect long-term success. Using CI as a procedural end point, we achieved excellent VT-free survival at least comparable to those reported in other studies in which substrate modification and standard procedural end points were used. In the Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial, a randomized controlled trial that investigated a strategy of early substrate-based VT ablation among patients with ischemic heart disease, freedom from treated ventricular arrhythmias was 88% at 2 years. 5 Using a similar strategy among patients with ischemic VT randomized to ablation+ICD versus ICD alone in the Ventricular Tachycardia Ablation in Coronary Heart Disease study, Kuck et al 6 observed a VT-free rate of 47% at 2 years. More recently, Di Biase et al 8 achieved a VT-free survival rate of 81% at 2 years using a technique of extensive endo and epicardial scar homogenization among patients with ischemic VT and no prior cardiac surgery. Our series provides proof of concept that CI and good ventricular arrhythmia control can be achieved among patients with both ischemic and nonischemic etiologies of structural heart disease and that CI may be a valuable adjunct to VT noninducibility as an ablation end point.
Also importantly, the rate of epicardial access and ablation required in this study was not higher than that previously reported for standard VT ablation approaches 29 and was lower in comparison with other contemporary approaches. 8, 12, 13 Importantly, we still were able to achieve CI in a majority of patients without epicardial ablation. One of the key factors that may have influenced this degree of success may have been the presence of intramural substrate, particularly among patients with nonischemic heart disease. [30] [31] [32] Such substrate has been demonstrated to provide relative compartmentalization of Figure 4 . Flowchart detailing long-term freedom from ventricular tachycardia (VT) rates based on acute VT noninducibility and core isolation (CI). Those in whom both VT noninducibilty and CI were achieved had the best VT-free survival. Notably, freedom from recurrent VT was still good among those in whom VT was still inducible but CI was achieved. diseased myocardium; this may have conferred an advantage that allowed more targeted ablation and without the need to achieve fully transmural ablation lesions to achieve isolation of critical VT elements. 30, 32 Rather, when ablating within areas of low voltage in ischemic or nonischemic scar, the endocardial lesion just needs to penetrate to the intramyocardial scar barrier (Figure 6 ).
Reasons for VT recurrence using the CI approach are likely no different than for any of the previously mentioned approaches and include novel VT arising from a region remote from that targeted or recurrent conduction across lines of block, similar to pulmonary vein reconnection. Reasons for continued acute VT inducibility after CI are similar, but probably weighted more to the former reason, as persistent CI was confirmed if VT remained inducible. We were unable to achieve CI in a small number of patients, which could have been because there were deep tracts of critical circuitry interspersed amid incongruous scar; this could lead to preferential conduction via alternate exits (epicardial or endocardial), thus bypassing more relatively superficial lines of ablation. Alternatively, potentially small residual gaps in existing lines despite repeated ablation application could have persisted, sheltered by surrounding edema from other lesions. Further study of this technique, coupled with imaging around the time of ablation, may provide more definitive answers. For the moment, however, the data from this study indicate that CI is a comparably achievable end point as VT noninducibility is, and adds incremental benefit in achieving ablation success.
Limitations
This study was observational and lacked a control group, and the sample size was relatively small, which limits interpretation of multivariable analysis. Patient selection for CI was based on operator preference, which could have introduced selection bias. Only patients with arrhythmogenic substrate identified by bipolar voltage mapping were included; this strategy thus cannot be extended to those with purely intramural myocardial substrate in which bipolar voltage may seem normal. Additionally, because of patient safety or length of procedure, reassessment of durable CI after a waiting period was not performed. This effort could improve outcomes and warrants additional investigation. The patients that did recur after CI had VT with site of origin or exit from within the pre-existing scar. Even in the absence of this step, none of the patients recurred with VT storm, and there was no evidence of proarrhythmia after ablation.
Additional substrate modification, occasionally including epicardial ablation, was performed in many patients because of either continued VT inducibility or operator preference to reinforce lesion sets. Doing so did not contribute significantly to freedom from recurrent VT. There is inevitable overlap in regions that would be targeted using other recently reported approaches for VT ablation, although ours may have been more limited in proportionate area of ablation.
8,12-14 NICM patients comprised less than one third of patients in this study, which somewhat limits generalizability and precludes detailed analysis of this group alone. However, cause of VT substrate was not significantly associated with either achievement of CI or VT recurrence after CI ablation.
The higher rate of inducibility with NIPS observed after ablation compared with acute inducibility postprocedurally is difficult to interpret because not all patients underwent NIPS. Only 1 patient had clinical VT inducible at NIPS, which makes recovery of conduction an unlikely general mechanism for recurrence; there may have been substrate characteristics not readily apparent at the time of ablation. Inducibility of VT, primarily nonclinical, at the time of NIPS was not predictive of VT recurrence, although the relatively small number who underwent NIPS limits interpretation.
Despite these limitations, we feel that the data presented are compelling, were noted at 2 institutions, and clearly substantiated the ability to isolate critical areas of endocardium that demonstrate surrogates of the VT circuit, providing a unique end point for assessing effect of the ablation. The results encourage future prospective study comparing CI with other substratebased ablation strategies, especially among an even more heterogeneous population than were included in this study.
Conclusions
CI is an achievable, easily assessed end point for ablation of ventricular arrhythmias among patients with ischemic or nonischemic heart disease, especially in the face of multiple or unmappable VTs. It is a strategy that may improve long-term ablation outcomes beyond acute noninducibility of VT without the need for extensive substrate-based ablation.
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